This Week in Cardiology — Jul 31, 2026

Welcome to This Week in Cardiology. This week we're covering six notable papers spanning advanced surgical and interventional outcomes, tailored pharmacotherapy in heart failure phenotypes, and the management of structural heart disease. Let's dive in.\n\nOur first theme focuses on surgical and interventional cardiology, where three new papers provide important insights into perioperative care, rhythm management, and valvular surgery. In a multicenter, double-blind, placebo-controlled randomized clinical trial published in JAMA, researchers investigated whether starting the sodium-glucose cotransporter-2 inhibitor dapagliflozin before elective cardiac surgery could prevent postoperative acute kidney injury [1]. The trial enrolled 784 participants, with 778 completing follow-up. This cohort had a median age of 68 years, was 76 percent male, and 97 percent White, with a median body mass index of 27 and a median estimated glomerular filtration rate of 80. Patients were randomized to receive either 10 milligrams of oral dapagliflozin or a matching placebo once daily, starting the day before surgery and continuing through the second postoperative day, for a total of four doses. The primary outcome was the difference in acute kidney injury during the first seven postoperative days. The trial demonstrated a substantial reduction in acute kidney injury, with the incidence falling from 52 percent in the placebo group to 28 percent in the dapagliflozin group, representing a relative risk of 0.54. Importantly, this benefit did not come with an increase in major complications; the incidence of postoperative atrial fibrillation was identical at 45 percent in both groups, and the rate of reoperation was nearly identical, at 11 percent with dapagliflozin versus 10 percent with placebo. Moving from perioperative pharmacotherapy to advanced heart failure interventions, an ancillary analysis of the CASTLE-HTx trial published in the European Journal of Heart Failure provides compelling support for early rhythm control in end-stage disease [3]. Using a generalized pairwise comparison methodology, the investigators analyzed 194 patients with end-stage heart failure and atrial fibrillation who were randomized to receive either catheter ablation combined with guideline-directed medical therapy, or medical therapy alone. The hierarchical composite included all-cause death, urgent heart transplantation, left-ventricular assist device implantation, and the frequency of hospitalizations for worsening heart failure. Patients randomized to catheter ablation experienced significantly more clinical wins. Specifically, the win rates for ablation versus medical therapy alone were 28.4 percent versus 12.4 percent for all-cause mortality, 4.3 percent versus 2.1 percent for heart transplantation, 4.2 percent versus 0.6 percent for assist device implantation, and 24.8 percent versus 11.3 percent for worsening heart failure hospitalizations. Overall, this resulted in a restricted net treatment benefit of 35.3 percent at three years, strongly favoring the ablation strategy with win odds of 2.09. Secondary analyses, which integrated atrial fibrillation burden and left-ventricular ejection fraction improvement, further reinforced this benefit with a net treatment benefit of 38.4 percent and win odds of 2.25. Completing our look at surgical and interventional outcomes is a population-based cohort study from the SWEDEHEART registry published in Heart, which addresses the challenging clinical scenario of prosthetic valve endocarditis [6]. The investigators evaluated 2,585 patients who underwent aortic valve surgery for endocarditis in Sweden between 1997 and 2022. Of these, 685 patients had prosthetic valve endocarditis, while 1,900 had native valve endocarditis. Patients with prosthetic valve endocarditis were typically older, with a median age of 68 compared to 61 in the native valve group, and they carried a higher burden of baseline comorbidities. During a mean follow-up of 7.1 years, the researchers observed that the 30-day mortality was significantly higher in the prosthetic valve group, at 12 percent compared to 6.1 percent in the native valve group, corresponding to an adjusted odds ratio of 1.76. However, the most encouraging finding emerged when analyzing long-term survival among those who survived past the initial 30 days. For these patients, the ten-year survival was remarkably similar between the two groups, with an absolute survival difference of only minus 4.6 percent. This suggests that while the perioperative period is higher risk for prosthetic valve endocarditis, patients who survive the first month can expect a long-term prognosis comparable to those with native valve endocarditis.\n\nNext, we turn to the medical management of heart failure, where two new publications emphasize the importance of identifying specific phenotypes and managing systemic comorbidities. In a large-scale observational study published in the European Journal of Heart Failure, researchers examined the impact of target-dose versus below-target-dose angiotensin-converting enzyme inhibitors in United States Veterans with heart failure with preserved ejection fraction [5]. The study analyzed 96,473 veterans newly initiated on these medications, matching 30,580 patients on target doses with an equal number of patients on below-target doses using a propensity score matching system. Over a five-year follow-up period, patients receiving target doses had an 11 percent lower risk of developing kidney failure. However, there was no difference in all-cause mortality, and target-dose therapy was actually associated with an 8 percent higher risk of heart failure hospitalization. A critical finding emerged when the investigators stratified the cohort by kidney function. Among the 16,735 patients with pre-existing chronic kidney disease, defined as an estimated glomerular filtration rate between 15 and 59, target-dose therapy was associated with an 18 percent lower risk of kidney failure and a 7 percent lower risk of mortality, without any increase in the risk of heart failure hospitalization. These differences between patients with and without chronic kidney disease were highly statistically significant, highlighting that the benefits of target-dose angiotensin-converting enzyme inhibitors in heart failure with preserved ejection fraction are heavily concentrated in, and perhaps unique to, patients with concurrent chronic kidney disease. This focus on multi-organ interaction is mirrored in an international expert position paper, also published in the European Journal of Heart Failure, which provides a comprehensive framework for managing the intersection of heart failure and liver disease [4]. The authors outline the shared risk factors and bidirectional pathophysiology of these two conditions, noting that their coexistence is expected to rise. Clinical management is frequently complicated by several factors, including the systemic under-representation of liver disease patients in landmark heart failure trials, altered drug metabolism, and impaired hemodynamics in advanced liver disease. The position paper highlights diagnostic pitfalls, such as the difficulty of differentiating primary liver disease and fibrosis from passive congestion caused by heart failure. To address these challenges, the authors advocate for integrated cardiovascular-hepatic research, targeted clinical education, and multidisciplinary healthcare services to optimize clinical care and improve patient outcomes.\n\nFinally, we explore a compelling therapeutic crossover between structural heart disease and neurology, focusing on the management of migraine in patients with a patent foramen ovale. In a multicenter, randomized, active-controlled, open-label trial published in the BMJ, investigators evaluated the efficacy and safety of antithrombotic therapy for migraine prevention in this specific patient population [2]. The trial enrolled 1,000 adults across 39 centers in China who had a confirmed patent foramen ovale and at least four migraine days per month. After a 12-week screening period, 984 participants were randomized to receive either high-dose aspirin at 300 milligrams daily, clopidogrel at 75 milligrams daily, rivaroxaban at 20 milligrams daily, or metoprolol at 25 milligrams twice daily for 12 weeks. The primary endpoint was the proportion of patients achieving at least a 50 percent reduction in monthly migraine days or attacks during the final month of treatment. The trial met its primary non-inferiority endpoints, demonstrating that aspirin, clopidogrel, and rivaroxaban were all non-inferior to metoprolol. The responder rates were 61.7 percent for aspirin, 66.8 percent for clopidogrel, and 61.8 percent for metoprolol. Notably, the rivaroxaban group achieved a responder rate of 78.4 percent, which was statistically superior to metoprolol, representing an absolute difference of 16.2 percent. Furthermore, rivaroxaban was associated with greater reductions in migraine days, higher rates of complete migraine cessation, and superior quality-of-life scores. Importantly, these clinical benefits were achieved without any major bleeding events in any of the treatment arms, suggesting that antithrombotic agents, particularly direct oral anticoagulants like rivaroxaban, may represent a highly effective alternative to traditional beta-blockers for migraine prevention in patients with a patent foramen ovale.\n\n If you only have time for one paper this week, make it the randomized trial of dapagliflozin for the prevention of acute kidney injury after cardiac surgery, published in JAMA [1]. This study provides a simple, short-course pharmacological intervention that remarkably cut the rate of post-surgical acute kidney injury nearly in half, offering a highly practical, low-cost strategy for a common and serious surgical complication.\n\n Here are the key takeaways from this week in Cardiology: First, initiating a short, four-dose course of dapagliflozin starting the day before elective cardiac surgery significantly reduces the incidence of postoperative acute kidney injury without increasing adverse events like atrial fibrillation or reoperation. Second, in patients with end-stage heart failure and atrial fibrillation, combining catheter ablation with guideline-directed medical therapy provides a significant clinical advantage over medical therapy alone, primarily driven by reductions in mortality and heart failure hospitalizations. Third, target-dose angiotensin-converting enzyme inhibitors in patients with heart failure with preserved ejection fraction provide clear survival and renal benefits specifically in the subgroup with coexisting chronic kidney disease, whereas those without chronic kidney disease may experience a higher risk of heart failure hospitalization without a survival benefit. Fourth, while patients undergoing aortic valve surgery for prosthetic valve endocarditis face higher 30-day mortality compared to those with native valve endocarditis, long-term survival among those who survive the first month is highly comparable. And finally, antithrombotic therapies, particularly rivaroxaban, are non-inferior—and in the case of rivaroxaban, superior—to metoprolol for migraine prevention in patients with a patent foramen ovale, without increasing the risk of major bleeding.\n\nThat's your roundup for This Week in Cardiology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.